231 related articles for article (PubMed ID: 31141090)
21. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
22.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract][Full Text] [Related]
23. The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10.
Archangelo LF; Gläsner J; Krause A; Bohlander SK
Oncogene; 2006 Jul; 25(29):4099-109. PubMed ID: 16491119
[TBL] [Abstract][Full Text] [Related]
24. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.
Mulaw MA; Krause A; Deshpande AJ; Krause LF; Rouhi A; La Starza R; Borkhardt A; Buske C; Mecucci C; Ludwig WD; Lottaz C; Bohlander SK
Leukemia; 2012 May; 26(5):1012-9. PubMed ID: 22064352
[TBL] [Abstract][Full Text] [Related]
25. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.
Dreyling MH; Martinez-Climent JA; Zheng M; Mao J; Rowley JD; Bohlander SK
Proc Natl Acad Sci U S A; 1996 May; 93(10):4804-9. PubMed ID: 8643484
[TBL] [Abstract][Full Text] [Related]
26. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
Chen L; Deshpande AJ; Banka D; Bernt KM; Dias S; Buske C; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Leukemia; 2013 Apr; 27(4):813-22. PubMed ID: 23138183
[TBL] [Abstract][Full Text] [Related]
27. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L.
Okada Y; Jiang Q; Lemieux M; Jeannotte L; Su L; Zhang Y
Nat Cell Biol; 2006 Sep; 8(9):1017-24. PubMed ID: 16921363
[TBL] [Abstract][Full Text] [Related]
28. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.
Helbling D; Mueller BU; Timchenko NA; Hagemeijer A; Jotterand M; Meyer-Monard S; Lister A; Rowley JD; Huegli B; Fey MF; Pabst T
Proc Natl Acad Sci U S A; 2004 Sep; 101(36):13312-7. PubMed ID: 15326310
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
Schmidt L; Heyes E; Grebien F
Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
[TBL] [Abstract][Full Text] [Related]
30. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
31. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
33. Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.
Caudell D; Harper DP; Novak RL; Pierce RM; Slape C; Wolff L; Aplan PD
Blood; 2010 Feb; 115(6):1194-203. PubMed ID: 20007546
[TBL] [Abstract][Full Text] [Related]
34. Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.
Kundu M; Chen A; Anderson S; Kirby M; Xu L; Castilla LH; Bodine D; Liu PP
Blood; 2002 Oct; 100(7):2449-56. PubMed ID: 12239155
[TBL] [Abstract][Full Text] [Related]
35. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.
Chim CS; Wong AS; Kwong YL
Br J Haematol; 2002 Dec; 119(4):988-90. PubMed ID: 12472578
[TBL] [Abstract][Full Text] [Related]
36. The role of CALM-AF10 gene fusion in acute leukemia.
Caudell D; Aplan PD
Leukemia; 2008 Apr; 22(4):678-85. PubMed ID: 18094714
[TBL] [Abstract][Full Text] [Related]
37. AF10 plays a key role in the survival of uncommitted hematopoietic cells.
Chamorro-Garcia R; Cervera M; Arredondo JJ
PLoS One; 2012; 7(12):e51626. PubMed ID: 23284727
[TBL] [Abstract][Full Text] [Related]
38. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
39. Alternative splicing in wild-type AF10 and CALM cDNAs and in AF10-CALM and CALM-AF10 fusion cDNAs produced by the t(10;11)(p13-14;q14-q21) suggests a potential role for truncated AF10 polypeptides.
Silliman CC; McGavran L; Wei Q; Miller LA; Li S; Hunger SP
Leukemia; 1998 Sep; 12(9):1404-10. PubMed ID: 9737689
[TBL] [Abstract][Full Text] [Related]
40. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
